- Details
- Hits: 4
Supervised consumption sites were sold as a disciplined, tightly monitored answer to the overdose crisis. In Alberta, the evidence suggests something far messier: weak oversight, fuzzy statistics, rising disorder, and a public policy that keeps asking citizens to trust what it does not fully measure. The claim that these facilities are “safe” has become a rhetorical shield, not a serious description of reality.
The sites may prevent some immediate drug poisonings, but the Alberta review and related reporting (among other evidence and an ever-increasing deluge of site situated negative community anecdata) raise serious concerns about transparency, neighbourhood disorder, weak treatment linkage, and a widening gap between what the sites promise and what they actually deliver.
One prominent piece of research, the Alberta review, is hard to read as anything other than a warning. It describes inconsistent record-keeping, undefined terms like “overdose” and “reversal,” and reporting practices that blurred the line between a genuine naloxone rescue and something far less dramatic, such as oxygen administration. That is not transparency. It is branding.
Then there is the small but crucial footnote in the B.C. coroner’s report: “no deaths” at supervised consumption sites does not include cases where the injury happened at the site and death occurred later in hospital. That distinction matters. It means the headline statistic can flatter the model while quietly excluding the worst outcomes. In public policy, what gets left out of the count often matters as much as what gets included.
The neighbourhood impact is where the smiley-face narrative really falls apart. Alberta’s review records persistent complaints about discarded needles, loitering, open drug use, urination, defecation, harassment, theft, and visible drug dealing around several sites. It also found that calls for service and social disorder often rose more sharply near the sites than in surrounding areas. To residents and businesses, that is not abstract “discomfort.” It is a daily loss of safety, dignity, and faith that public space still belongs to the public.
If that still sounds like a sterile list of grievances, consider the kind of firsthand account that rarely makes it into the policy briefs. Toronto-based investigative journalist Derek Finkle has described living across the street from the South Riverdale Community Health Centre in Leslieville, where an injection site began operating in late 2017. He has recounted watching the neighbourhood shift from the pre-site baseline, through the early months, into what he says became a prolonged period of escalating frustration among residents and local business owners—followed, in his telling, by a sense of being routinely dismissed when concerns were raised.
He has also described neighbours feeling compelled to document what they were seeing themselves—using a shared incident log and photographs—because official channels did not appear to capture the everyday reality on the perimeter. In a short window of roughly three and a half weeks, he says the community recorded close to 150 separate incidents. The pattern he describes mirrors the Alberta complaints almost point for point: open drug use, assaults, lewd behaviour, discarded needles, visible dealing, and the predictable intimidation that follows when drug markets harden around a fixed location.
And the policy drift is obvious. These sites were justified as a response to the opioid crisis, yet the Alberta review shows substantial methamphetamine use at some locations, including inhalation booths that widened the model beyond its original purpose. Naloxone can reverse opioids. It does nothing for stimulant psychosis, aggression, or the erratic behaviour that communities are left to absorb after users walk back onto the street. A program built for one crisis should not be judged successful simply because it keeps expanding into other crises.
The deeper failure is that supervised consumption has too often become an endpoint rather than an entry point. The Alberta review found weak evidence that sites consistently moved people into detox, treatment, or recovery, and it criticized the whole system for leaning toward “permanent maintenance” rather than genuine exit routes from addiction. That is the uncomfortable truth proponents rarely emphasize: if a site does not meaningfully connect people to recovery, then it risks becoming a holding pattern for despair.
None of this means every supervised consumption site is identical, or that every study points the same way. Some research has found reductions in poisoning mortality and ambulance calls in certain settings. But a serious society does not settle for slogans on either side. It asks harder questions: Who is being helped? Who is bearing the cost? What is actually being counted? And what happens to the neighbourhood when a policy built on compassion stops being accountable?
Finkle’s account becomes still harder to wave away because, in his telling, the frustration did not remain merely rhetorical. He has linked the breakdown in order around the site to a neighbourhood tragedy: a woman killed by stray gunfire during an alleged dispute among drug dealers nearby—an event that, he notes, only forced attention onto issues residents felt had been minimized for months. He has also pointed to the ensuing controversy in which a harm reduction worker connected to the site was arrested and charged as an accessory after the fact and with obstructing justice—an extreme and rare allegation, but a useful illustration of the broader point here: when systems are insulated from scrutiny, the public is asked to accept reassurances even when events demand documentation, clear lines of responsibility, and verifiable oversight.
The real scandal is not that the debate exists. It is that governments have allowed it to be conducted with so little rigor. If these sites are to continue, they must be subjected to clear audits, independent oversight, standardized reporting and honest reporting on treatment outcomes, neighbourhood impacts, and adverse events.
Anything less is not harm reduction – it is policy by fog.
(Source: WRD News Team)
- Details
- Hits: 38
A New Lens: Research Domain Criteria
Researchers from UCLA took a different approach. Rather than relying solely on clinical diagnoses in the NVDRS, they used the Research Domain Criteria (RDoC) framework. Developed by the National Institute of Mental Health, RDoC looks at psychological functioning across six broad domains:
- Negative valence (distress, hopelessness, anxiety)
- Positive valence (motivation, reward, substance use patterns)
- Social processes (relationships, belonging)
- Arousal processes (agitation, sleep disturbance)
- Cognitive systems (attention, memory, decision-making)
- Sensorimotor systems
Rather than asking “does this person have a diagnosis?”, RDoC asks: “in what ways was this person’s psychological functioning disrupted?”
To extract this from NVDRS death narratives, the researchers applied two machine learning methods. One was a token-based scoring system. The other was a large language model (LLM), the technology behind modern AI tools. Both had previously been validated against psychiatric inpatient records.
What the Research Found About Psychological Dysfunction and Suicide
The study analysed death records for 72,585 people who died by suicide in 2020 and 2021. These came from all 50 US states. The results were striking.
Using the LLM scoring method, more than 90% of suicide decedents showed at least one clinically significant RDoC domain score. This means evidence of dysfunction serious enough to require treatment. It was true in both law enforcement and coroner narratives.
Compare that to what the NVDRS had recorded: only 44.4% with any mental health disorder and only 27.9% described as currently depressed.
The domains most frequently elevated were negative valence and arousal processes. These capture hopelessness, distress, anxiety, and agitation. These are emotional states that do not always lead to a formal diagnosis. Yet they are deeply relevant to suicide risk and mental health outcomes.
Female decedents and younger decedents showed consistently higher levels of dysfunction across most domains. Among younger adults aged 25 to 44, clinically relevant arousal process dysfunction appeared in around 65% of law enforcement narratives. Among those aged 65 and over, this figure dropped to around 41%. Even so, dysfunction remained widespread in that older group.
Substance Use and Psychological Dysfunction and Suicide
One finding deserves particular attention. The RDoC framework links positive valence dysfunction directly to substance use patterns and their effects on reward processing. This dysfunction was significantly more common among decedents than standard NVDRS alcohol and drug measures suggested.
The standard NVDRS measure recorded problematic alcohol or drug use in 27.5% of decedents. But RDoC positive valence dysfunction, which captures disrupted reward and motivation, showed clinically relevant levels in around 31 to 41% of decedents.
Substance use does not just create health risks in isolation. It fundamentally alters how people experience reward, motivation, and relief from distress. It reshapes emotional life in ways that heighten vulnerability. That connection is essential to understand.
Why This Changes the Conversation
The traditional approach to suicide prevention has often focused on identifying people with a clinical diagnosis. If someone has a recorded diagnosis of depression or an anxiety disorder, systems are more likely to flag them for intervention. But a large proportion of people who die by suicide do not have that flag.
The RDoC approach offers a different way in. By looking at how someone is actually functioning, it is possible to detect risk that a diagnosis alone would miss.
This is especially relevant for men. Men made up 80.6% of decedents in this study. They were consistently less likely than women to have formal mental health diagnoses recorded. The suffering was still there. It was simply less likely to have been named.
(Complete Research: JAMA Network)
- Details
- Hits: 137
A groundbreaking study published in the May 2026 issue of Anesthesiology has raised serious concerns about naloxone overdose reversal when potent synthetic opioids are involved. Researchers found that one standard dose may not be enough to fully protect a person in crisis. The findings carry urgent implications for anyone on the front lines of the ongoing drug crisis.
Dr Maarten A. van Lemmen of Leiden University Medical Center in the Netherlands led the research. His team tested a single 4mg intranasal dose of Narcan against respiratory depression triggered by fentanyl and sufentanil. Both are synthetic opioids with an exceptionally strong grip on the brain’s opioid receptors.
What the Study Found About Naloxone Overdose Reversal
The trial involved 30 participants split into two groups. Twelve had never used opioids and 18 reported using opioids every day. Researchers gave each person a continuous infusion of either fentanyl or sufentanil, enough to reduce breathing by 30 to 40 per cent, before administering intranasal naloxone.
The results painted a troubling picture. Narcan restored normal breathing rates within two to four minutes across all participants. However, carbon dioxide levels recovered far more slowly, taking between 11 and 17 minutes on average. That gap matters because carbon dioxide clearance reflects whether the lungs are actually working properly.
The picture grew more concerning with sufentanil, a drug roughly ten times more potent than fentanyl. Carbon dioxide levels never fully returned to normal in a significant proportion of subjects. Only 8 of 12 opioid-naive individuals showed complete recovery. Among daily opioid users, 10 of 12 recovered fully.
“Delayed and sometimes incomplete recovery of end-tidal carbon dioxide, particularly during exposure to the high-affinity opioid sufentanil, indicates reversal inefficacy and persistence of respiratory instability,” the authors concluded.
The Gap Between Looking Awake and Being Safe
One of the most striking findings concerns how a person looks after receiving naloxone versus how their body is actually functioning. A person can appear alert and responsive long before their breathing stabilises. An accompanying editorial by James P. Rathmell, editor-in-chief of Anesthesiology and Professor of Anaesthesia at Harvard Medical School, flagged this as a serious safety risk.
“This distinction has immediate implications for patient safety, observation practices, and dosing strategies,” Dr Rathmell and co-author Steven E. Kern wrote. They explained that re-sedation and delayed respiratory instability can still occur even after intranasal naloxone administration.
Someone who appears to have woken up may still be in serious danger. This is especially true with very high-affinity synthetic opioids like sufentanil and, by extension, carfentanil, which binds to receptors even more tightly.
The Scale of the Crisis and Why Naloxone Overdose Reversal Is Harder Now
Synthetic opioids now dominate the overdose landscape. Fentanyl and related drugs account for an estimated 60 to 79 per cent of overdose deaths in the United States. Over the past two decades, roughly 800,000 Americans have died from drug overdoses, the vast majority involving potent opioids. Their molecular grip on opioid receptors makes the standard naloxone overdose reversal protocol increasingly inadequate.
The study also recorded a phenomenon known as renarcotisation. After the initial reversal, breathing rate, carbon dioxide levels, and pupil size all drifted back towards opioid-suppressed levels as naloxone wore off. A single dose simply does not last long enough when a potent opioid remains in the system.
Naloxone Overdose Reversal and Withdrawal: Another Layer of Risk
Among the 18 daily opioid users in the trial, nine experienced withdrawal symptoms after receiving naloxone. Symptoms ranged from agitation and nausea to hypertension and vomiting. Seven participants withdrew from the study because of this. For people who use opioids regularly, the reversal process can itself become a crisis.
Symptoms typically started around 20 minutes after naloxone administration and peaked at roughly 30 minutes. All resolved within two hours. Still, this reaction creates real challenges for emergency responders working in unpredictable settings.
What This Means for Overdose Response
The study’s authors are direct on what practitioners should take away. A single naloxone dose cannot reliably reverse overdoses involving high-affinity synthetic opioids. Calling emergency services immediately remains essential, even when the drug appears to have worked. Multiple doses may be necessary. Close monitoring must continue long after the person regains consciousness.
Current overdose response guidelines developed around heroin, which binds to receptors far less powerfully than fentanyl. The drug supply has shifted dramatically. Those protocols now need urgent revision.
“Further studies are needed to address optimal naloxone doses and alternative formulations to address high-dose potent opioid threats,” the research team noted.
A Call for Updated Thinking on Intranasal Naloxone
The study does carry limitations. Laboratory infusions differ from real-world overdoses, where opioid levels spike then fall naturally. That natural decline may assist recovery in ways the experiment could not replicate. The level of respiratory depression induced, 30 to 40 per cent below baseline, was also moderate. Real overdoses often involve complete cessation of breathing, making a single intranasal naloxone dose even less likely to suffice.
A separate study by the same team found that when fentanyl caused full apnea, patients needed two to four Narcan doses to restore normal breathing. Together, the findings confirm that naloxone overdose reversal is not a one-and-done solution against today’s synthetic drugs.
Naloxone saves lives. But it is not a guarantee, and it was never a substitute for emergency medical care. Knowing its limits and acting on that knowledge could be the difference between survival and tragedy.
(Source: WRD News)
- Details
- Hits: 95
Young people struggling with youth drug treatment needs have long been underserved by a system built around adults. That is now changing. The American Society of Addiction Medicine (ASAM) has published a landmark framework dedicated entirely to substance use disorder care for adolescents and young adults under 25, separating their standards from adult guidance for the first time.
The new volume, titled the Adolescent and Transition-Aged Youth edition of The ASAM Criteria, sets out the full range of services that should be available to every young patient. Previously, adolescent addiction treatment standards sat buried within adult-focused criteria, a setup that many clinicians had criticised for years.
Brain development continues well into a person’s mid-twenties. That biological reality shapes the entire framework. Young people are not simply smaller adults, and the risks they face from substance use reflect that difference.
Why Youth Drug Treatment Needs Its Own Framework
The numbers make a sobering case. Around 80% of adults living with substance use disorder started using substances before the age of 18. Those who begin before 15 are 6.5 times more likely to develop a dependency than those who wait until 21 or older. Early exposure does not just raise risk. It can reshape development, delay the acquisition of life skills, and set a difficult course for decades to come.
“Ongoing brain development during these formative years puts youth at a greater risk of developing the disease of addiction, which can lead to poor health outcomes and delayed life skill development,” said Dr Corey Waller, editor-in-chief of the new volume.
The ASAM now recommends early intervention for any young person already using substances and showing signs of rapid escalation. Waiting for a formal diagnosis before acting is no longer the preferred approach.
Adolescent Addiction Treatment: A Holistic, Family-Centred Model
The updated standards place the young person firmly at the centre, but they also widen the lens considerably. The framework promotes a model that brings in mental health services, connects with schools and community networks, and treats prevention as seriously as treatment itself.
This matters because youth drug treatment challenges rarely travel alone. Most adolescents dealing with substance-related difficulties also carry co-occurring mental health conditions. The new guidance pushes clinicians to address both at the same time, not in sequence.
The continuum of care expands too. New service levels include ongoing remission monitoring and integrated withdrawal management within youth-specific programmes. These are areas that existing guidance had largely overlooked.
Rising Risks Make the Case for Change
The clinical picture for young people has grown more complex in recent years. Fentanyl and other high-potency substances now reach adolescents far more readily than before. Clinicians report encountering levels of risk in young patients that would have been uncommon a decade ago.
“While there will be challenges to overcome to make this vision a reality, we must commit to building systems and payment models capable of delivering effective interventions and treatments for all young people who need them,” said Dr Waller.
Putting the New Standards Into Practice
ASAM presented the new criteria on 25 March at the Joint Meeting on Youth Prevention, Treatment, and Recovery. The Hazelden Betty Ford Foundation published the complete volume online and will release a print edition in June.
The Foundation also built a digital interface to help clinicians across the full care team put adolescent addiction treatment into practice without friction.
“The ASAM Criteria’s new adolescent treatment standards represent a tremendous opportunity to further elevate and individualise care for our nation’s children and young adults,” said Dr Joseph Lee, president and chief executive of the Hazelden Betty Ford Foundation.
The framework asks more than clinicians to act. It calls on commissioners, policymakers and system leaders to fund and build the infrastructure these standards require. With the evidence pointing clearly to adolescence as the window where intervention matters most, getting that infrastructure right carries consequences that stretch well beyond the clinic.
(Source: WRD News)
- Details
- Hits: 212
The choices you make in your twenties may feel a world away from who you will be at 65. But a landmark new study from the University of Michigan suggests the brain keeps a much longer record than most of us realise. Researchers found that young adult substance use, including binge drinking, frequent cannabis use, and daily cigarette smoking between the ages of 18 and 30, links significantly to poorer self-reported memory in midlife, between the ages of 50 and 65.
The findings appear in the Journal of Aging and Health. The National Institute on Drug Abuse funded the work, making it one of the first studies to track these patterns across multiple decades of a person’s life.
A Study Decades in the Making
The research drew on data from the Monitoring the Future Longitudinal Panel Study. It followed participants from age 18, as far back as 1976, through to their mid-sixties. This long view let researchers see not just what people did in their youth, but what those habits ultimately cost them.
“Substance use has both acute and long-term effects on health and well-being,” said Megan Patrick, research professor at the Institute for Social Research. “Poor memory is a common sign of early dementia. We examined whether young adult substance use links to poor memory decades later in midlife.”
The study spanned nearly five decades. It captured real behavioural patterns across generations of young Americans, giving its conclusions real weight.
How Young Adult Substance Use Damages the Brain: Two Different Pathways
Not all substances damage the brain in the same way. The team identified a “triple threat”: binge drinking, near-daily cannabis use, and daily cigarette smoking in young adulthood. All three connect to memory problems in later life, but through entirely different mechanisms.
Cigarettes: the direct threat
Daily smoking between 18 and 30 predicted poorer memory in early midlife. Crucially, this held true even for people who stopped smoking by age 35. Quitting later in life does not appear to undo what cigarettes do to the developing brain during young adulthood.
Young brains are still forming during this period. Cigarette toxins appear to leave a mark that persists for decades, regardless of what happens afterwards.
Alcohol and cannabis: the addiction route
For binge drinking and frequent cannabis use, the picture differs. Heavy substance use in young adulthood does not directly cause memory loss thirty years later. Instead, it raises the likelihood of developing a Substance Use Disorder (SUD) in the thirties. That ongoing disorder then drives poorer cognitive functioning later in life.
This distinction matters enormously. For alcohol and cannabis, the window for intervention does not close at 30. Treating a substance use disorder in midlife could still help protect the brain.
“Even if someone thinks their current substance use may not be problematic because they don’t see it as affecting their health right now, there are still potential longer-term consequences to consider,” Patrick said.
What the Numbers Say About Heavy Substance Use in Young Adulthood
Self-reported poor memory is an early marker of cognitive decline and, in some cases, an early sign of dementia. Dementia now affects an estimated 55 million people worldwide, according to the World Health Organisation. That figure could reach 139 million by 2050, making early-life risk factors a pressing public health concern.
The study found that all three forms of heavy substance use in young adulthood directly associated with higher odds of poor self-rated memory in late midlife. For alcohol and cannabis, substance use disorder symptoms in early midlife fully explained those associations. For pack-a-day or heavier cigarette smoking, no such explanation applied, pointing to direct neurological damage instead.
Why Young Adult Substance Use Puts the Developing Brain at Risk
The brain does not finish developing until the mid-twenties. The prefrontal cortex, the region that handles decision-making, emotional regulation, and memory formation, is among the last areas to mature. Young adulthood is therefore a period of heightened neurological sensitivity.
“Young adulthood is a critical period for brain development,” Patrick noted. “Substance use patterns established during this period may have lasting consequences on memory and cognitive health much later in life.”
Heavy substance use in young adulthood is not simply a lifestyle choice with short-term effects. The evidence suggests it may reshape the trajectory of cognitive ageing for decades.
What This Means If You Smoked or Drank Heavily in Your Twenties
For those who smoked daily in their youth and have since quit, the findings may feel alarming. Giving up cigarettes by 35 does not appear to cancel the earlier neurological impact. Even so, cognitive decline is not inevitable. Staying proactive about brain health matters more than ever: regular exercise, good sleep, mental stimulation, and avoiding further substance use all help.
For those who drank heavily or used cannabis often in their twenties, the outlook is more actionable. Memory decline in this group links to ongoing substance use disorders rather than past behaviour alone. Getting appropriate support and treatment in midlife remains a meaningful step worth taking.
“Understanding these risk factors and their trajectory across the lifespan will inform strategies to support cognitive health,” Patrick said.
The Case for Early Intervention Against Young Adult Substance Use
Early action works far better than trying to reverse damage later. Identifying and addressing substance use in young people, before patterns become entrenched and neurological costs accumulate, gives the brain its best chance.
“This study demonstrates potential long-term detrimental impacts of young adult heavy substance use on cognitive health later in life,” Patrick said. “It highlights the importance of early interventions.”
For public health, the implications are clear. Prevention and support programmes targeting young people protect far more than immediate wellbeing. They may be among the most powerful tools available for safeguarding a generation’s long-term cognitive health.
The study was published in the Journal of Aging and Health. Authors: Megan E. Patrick, Yuk C. Pang, Yvonne M. Terry-McElrath, and Joy Bohyun Jang, University of Michigan Institute for Social Research.
(Source: WRD News)
- The Hidden Crisis: Violence Against Women Who Use Drugs and Why So Few Get Help
- The Powerful Link Between Spirituality and Reduced Alcohol and Drug Use
- Prayer, Meditation and Faith Could Cut Your Risk of Alcohol and Drug Misuse, Harvard Study Finds
- One in Four Teens Face Neighbourhood Violence and Turn to Substances to Cope